ST. JOSEPH, Mo. – Boehringer Ingelheim Vetmedica, Inc., (BIVI) introduces the 3FLEX® 50 Doses HSB (head space bottle) vaccine for swine veterinarians and producers to control three of the most common respiratory diseases in pigs: porcine circovirus, Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome (PRRS).
Each 3FLEX® vaccine package contains a bottle of Ingelvac CircoFLEX®, Ingelvac MycoFLEX® and Ingelvac PRRS® MLV. The Ingelvac MycoFLEX® is supplied in a headspace bottle with extra capacity for purpose of aseptic mixing; making it easier to mix and administer all three vaccines in a single 2mL dose.
Sarah Jorgensen, senior brand manager, swine, for BIVI, says the significant production losses caused by these major swine diseases – PCV2, Mycoplasma, and PRRS – makes reducing the impact of these diseases even more important to producers and the swine industry.
“Recent research shows that while these diseases by themselves can reduce pig performance and increase mortality, co-infections of these diseases in combination can be particularly devastating, resulting in losses averaging more than $10 per pig1,” Jorgensen explains. “3FLEX® is an effective option when protection is needed against these three major diseases. Like all products in the FLEX family of swine vaccines, veterinarians and producers have the ability to customize their disease control programs by selecting the right monovalent or combination vaccine that best fits their herd.”
This new addition to the FLEX Family, 3FLEX® 50 Doses HSB, will be available starting spring of 2014. For more information about these swine vaccines, contact your veterinarian, visit www.bi-vetmedica.com, or call BIVI at 800-325-9167.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
Source: Boehringer Ingelheim